Development of a self-adjuvanting mucosal vaccine candidate against Group A Streptococcus using lipid core technology

利用脂质核心技术开发针对 A 组链球菌的自我辅助粘膜候选疫苗

• 批准号: nhmrc : 1069915
• 负责人: Dr Mehfuz Zaman
• 金额: $ 21.1万
• 依托单位: Griffith University
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-self-adjuvanting-core-technology/455417
• 关键词: Development; self; adjuvanting; mucosal; vaccine

Novel developments in drug/vaccine delivery are clearly to have enormous economic and social impacts. My research aim is to rationally design and develop vaccines against relevant diseases. By understanding the mechanism of protection against diseases, development of novel vaccines for the treatment of many diseases can be achieved. This would contribute enormously to the betterment of public health.

药物/疫苗输送方面的新发展显然会产生巨大的经济和社会影响。我的研究目的是合理设计和开发针对相关疾病的疫苗。通过了解预防疾病的机制，可以开发出治疗多种疾病的新型疫苗。这将极大地促进公共卫生。